Despite these encouraging trends, the market has hurdles, including due to the high cost of GLP-1 agonists, which may limit access for specific patient populations
In 2025, Williams opened up about her experience taking Zepbound, citing not only weight loss but improved health overall
The triple-agonist mechanism is new for the category
Second, the precise molecular targets and signaling pathways modulated by AP remain partially understood
All medications are available in all 50 states without insurance requirements, and HSA/FSA accounts cover the cost, making precision weight loss accessible to a broader population
Newer therapies are sought to maintain the benefits of sustained GLP-1R activation while minimising side effects and enhancing metabolic homeostasis combining GLP-1RA with GIP-RA may expand its therapeutic index [45]